Guidelines for the transfusion of platelets

Acta Clinica Belgica

Volumn 62, Issue 1, 2007, Pages 36-47

  Bosly, A ^a   Muylle, Ludo ^b,c   Noens, L ^d   Pietersz, R ^e   Heim, D ^f   Hubner R ^g   Selleslag, D ^h   Toungouz, M ⁱ   Ferrant, A ^j   Sondag, D ^k  

^a UNIVERSITY HOSPITAL OF MONT GODINNE   (Belgium)

^b Federal Agency for Medicines and Health Products Belgium   (Belgium)

^c UNIVERSITY OF ANTWERP   (Belgium)

^d GHENT UNIVERSITY HOSPITAL   (Belgium)

^e Sanquin Bloedbank Regio Noordwest Amsterdam   (Netherlands)

^f UNIVERSITY HOSPITAL BASEL   (Switzerland)

^g Superior Health Council   (Belgium)

^h General Hospital St Jan   (Belgium)

ⁱ ERASME HOSPITAL   (Belgium)

^j CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^k Hospital de Baviere   (Belgium)

more..

Author keywords

Indications; Platelets; Transfusion guidelines

Indexed keywords

HLA ANTIBODY; IMMUNOGLOBULIN; STEROID;

ACUTE LEUKEMIA; ANTIBODY DETECTION; AUTOPSY; BELGIUM; BLEEDING DISORDER; BLOOD GROUP ABO SYSTEM; DRUG MEGADOSE; HOSPITAL SERVICE; HUMAN; LUMBAR PUNCTURE; MEDICAL SOCIETY; PRACTICE GUIDELINE; PROPHYLAXIS; QUALITY CONTROL; REVIEW; SURGICAL TECHNIQUE; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TREATMENT INDICATION;

EID: 34047146538     PISSN: 00015512     EISSN: None     Source Type: Journal    
DOI: 10.1179/acb.2007.006     Document Type: Review

References (67)

1. Baele PL, De Bruyere M, Deneys V et al. The SANGUIS Study in Belgium: an overview of methods and results. Safe and good use of blood in surgery. Acta Chir Belg 1994;94:69-74.
2. Superior Health Council. Guidelines for the transfusion of platelets (8068), 2005.
3. Slichter SJ. Relationship between platelet count and bleeding risk in thrombocytopenic patients. Transfus Med Rev 2004;18:153-67.
4. Gaydos LA, Freireich EJ, Mantel N. The quantitative relation between platelet count and hemorrhage in patients with acute leukemia. N Engl J Med 1962;266:905-9.
5. Slichter SJ, Harker LA. Thrombocytopenia: mechanisms and management of defects in platelet production. Clin Haematol 1978;7:523-39.
6. Han T, Stutzman L, Cohen E, Kim U. Effect of platelet transfusion on hemorrhage in patients with acute leukemia. An autopsy study. Cancer 1966;19:1937-42.
7. Roy AJ, Jaffe N, Djerassi I. Prophylactic platelet transfusions in children with acute leukemia: a dose response study. Transfusion 1973;13:283-90.
8. Hamajima N, Sasaki R, Aoki K, Shibata A. A notable change in mortality of aplastic anemia observed during the 1970s in Japan. Blood 1988;72:995-9.
9. Higby DJ, Cohen E, Holland JF, Sinks L. The prophylactic treatment of thrombocytopenic leukemic patients with platelets: a double blind study. Transfusion 1974;14:440-6.
10. Williamson LM. Correcting haemostasis. Vox Sang 2004;87 Suppl1:51-7.
11. Schiffer CA, Anderson KC, Bennett CL et al. Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001;19:1519-38.
12. Sagmeister M, Oec L, Gmur J. A restrictive platelet transfusion policy allowing long-term support of outpatients with severe aplastic anemia. Blood 1999;93:3124-6.
13. Gibson BE, Todd A, Roberts I et al. Transfusion guidelines for neonates and older children. Br J Haematol 2004;124:433-53.
14. George JN. Idiopathic thrombocytopenic purpura in adults: current issues for pathogenesis, diagnosis and management. Hematol J 2004;5 Suppl 3:S12-4.
15. Guidelines for the use of platelet transfusions. British Committee for Standards in Haematology, Blood Transfusion Task Force. Br J Haematol 2003;122:10-23.
16. Avvisati G, Tirindelli MC, Annibali O. Thrombocytopenia and hemorrhagic risk in cancer patients. Crit Rev Oncol Hematol 2003;48:S13-6.
17. Wandt H, Ehninger G, Gallmeier WM. New strategies for prophylactic platelet transfusion in patients with hematologic diseases. Oncologist 2001;6:446-50.
18. Solomon J, Bofenkamp T, Fahey JL, Chillar RK, Beutel E. Platelet prophylaxis in acute non-lymphoblastic leukaemia. Lancet 1978;1:267.
19. Murphy S, Litwin S, Herring LM et al. Indications for platelet transfusion in children with acute leukemia. Am J Hematol 1982;12:347-56.
20. Stanworth SJ, Hyde C, Heddle N, Rebulla P, Brunskill S, Murphy MF. Prophylactic platelet transfusion for haemorrhage after chemotherapy and stem cell transplantation. In : The Cochrane Library. Issue 4. Chichester, UK: John Wiley & Sons, Ltd.; 2004: CD004269.pub2.
21. Heal JM, Blumberg N. Optimizing platelet transfusion therapy. Blood Rev 2004;18:149-65.
22. Heckman KD, Weiner GJ, Davis CS, Strauss RG, Jones MP, Burns CP. Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukemia: 10/microL versus 20/microL. J Clin Oncol 1997;15:1143-9.
23. Rebulla P, Finazzi G, Marangoni F et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto. N Engl J Med 1997;337:1870-5.
24. Zumberg MS, del Rosario ML, Nejame CF et al. A prospective randomized trial of prophylactic platelet transfusion and bleeding incidence in hematopoietic stem cell transplant recipients: 10,000/L versus 20,000/microL trigger. Biol Blood Marrow Transplant 2002;8:569-76.
25. Gmur J, Burger J, Schanz U, Fehr J, Schaffner A. Safety of stringent prophylactic platelet transfusion policy for patients with acute leukaemia. Lancet 1991;338:1223-6.
26. Segal HC, Briggs C, Kunka S et al. Accuracy of platelet counting haematology analysers in severe thrombocytopenia and potential impact on platelet transfusion. Br J Haematol 2005;128:520-5.
27. Howard SC, Gajjar A, Ribeiro RC et al. Safety of lumbar puncture for children with acute lymphoblastic leukemia and thrombocytopenia. Jama 2000;284:2222-4.
28. Edelson RN, Chernik NL, Posner JB. Spinal subdural hematomas complicating lumbar puncture. Arch Neurol 1974;31:134-7.
29. McVay PA, Toy PT. Lack of increased bleeding after liver biopsy in patients with mild hemostatic abnormalities. Am J Clin Pathol 1990;94:747-53.
30. Wallace MJ, Narvios A, Lichtiger B et al. Transjugular liver biopsy in patients with hematologic malignancy and severe thrombocytopenia. J Vasc Interv Radiol 2003;14:323-7.
31. Foster PF, Moore LR, Sankary HN, Hart ME, Ashmann MK, Williams JW. Central venous catheterization in patients with coagulopathy. Arch Surg 1992;127:273-5.
32. DeLoughery TG, Liebler JM, Simonds V, Goodnight SH. Invasive line placement in critically ill patients: do hemostatic defects matter? Transfusion 1996;36:827-31.
33. Tinmouth A, Tannock IF, Crump M et al. Low-dose prophylactic platelet transfusions in recipients of an autologous peripheral blood progenitor cell transplant and patients with acute leukemia: a randomized controlled trial with a sequential Bayesian design. Transfusion 2004;44:1711-9.
34. Sensebe L, Giraudeau B, Bardiaux L et al. The efficiency of transfusing high doses of platelets in hematologic patients with thrombocytopenia: results of a prospective, randomized, open, blinded end point (PROBE) study. Blood 2005;105:862-4.
35. Koninklijk besluit van 1 februari 2005 tot wijziging van het koninklijk besluit van 4 april 1996 betreffende de afneming, de bereiding, de bewaring en de terhandstelling van bloed en bloed-derivaten van menselijke oorsprong. Belgisch Staatsblad 2005;08.02.2005:3939-56.
36. Standards for Blood Banks and Transfusion Services. 16 ed. Bethesda, MD: American Association of Blood Banks; 1994.
37. Guide to the preparation, use and quality assurance of blood components. 10 ed. Strasbourg: Council of Europe Publishing; 2004:121-32.
38. Pietersz RN, van der Meer PF, Steneker I et al. Preparation of leukodepleted platelet concentrates from pooled buffy coats: prestorage filtration with Autostop BC. Vox Sang 1999;76:231-6.
39. Hillyer CD, Josephson CD, Blajchman MA, Vostal JG, Epstein JS, Goodman JL. Bacterial contamination of blood components: risks, strategies, and regulation: joint ASH and AABB educational session in transfusion medicine. Hematology (Am Soc Hematol Educ Program) 2003:575-89.
40. Commission directive 2004/33/EC of 22 March 2004 implementing Directive 2002/98/EC of the European Parliament and of the Council as regards certain technical requirements for blood and blood components. Official Journal of the European Union 2004;L91:25-31.
41. Simon TL, Sierra ER. Concentration of platelet units into small volumes. Transfusion 1984;24:173-5.
42. Holme S. Storage and quality assessment of platelets. Vox Sang 1998;74 Suppl 2:207-16.
43. Holme S, Moroff G, Murphy S. A multi-laboratory evaluation of in vitro platelet assays: the tests for extent of shape change and response to hypotonic shock. Biomedical Excellence for Safer Transfusion Working Party of the International Society of Blood Transfusion. Transfusion 1998;38:31-40.
44. Pietersz RN, Engelfriet CP, Reesink HW. Evaluation of stored platelets. International forum. Vox Sang 2004;86:203-23.
45. Dumont LJ, AuBuchon JP, Whitley P et al. Seven-day storage of single-donor platelets: recovery and survival in an autologous transfusion study. Transfusion 2002;42:847-54.
46. Slichter SJ. Platelet transfusion: future directions. Vox Sang 2004;87 Suppl 2:47-51.
47. de Wildt-Eggen J, Gulliksson H. In vivo and in vitro comparison of platelets stored in either synthetic media or plasma. Vox Sang 2003;84:256-64.
48. de Wildt-Eggen J, Nauta S, Schrijver JG, van Marwijk Kooy M, Bins M, van Prooijen HC. Reactions and platelet increments after transfusion of platelet concentrates in plasma or an additive solution: a prospective, randomized study. Transfusion 2000;40:398-403.
49. Oksanen K, Ebeling F, Kekomaki R et al. Adverse reactions to platelet transfusions are reduced by use of platelet concentrates derived from buffy coat. Vox Sang 1994;67:356-61.
50. Aster RH. Effect of anticoagulant and ABO incompatibility on recovery of transfused human platelets. Blood 1965;26:732-43.
51. Lee EJ, Schiffer CA. ABO compatibility can influence the results of platelet transfusion. Results of a randomized trial. Transfusion 1989;29:384-9.
52. Brand A, Sintnicolaas K, Claas FH, Eernisse JG. ABH antibodies causing platelet transfusion refractoriness. Transfusion 1986;26:463-6.
53. Carr R, Hutton JL, Jenkins JA, Lucas GF, Amphlett NW. Transfusion of ABO-mismatched platelets leads to early platelet refractoriness. Br J Haematol 1990;75:408-13.
54. Pierce RN, Reich LM, Mayer K. Hemolysis following platelet transfusions from ABO-incompatible donors. Transfusion 1985;25:60-2.
55. Richtlijn Bloedtransfusie. Kwaliteitsinstituut voor de Gezondheidszorg CBO. Alphen aan den Rijn: Van Zuiden Communications; 2004:255-7.
56. Moroff G, Garratty G, Heal JM et al. Selection of platelets for refractory patients by HLA matching and prospective crossmatching. Transfusion 1992;32:633-40.
57. Gelb AB, Leavitt AD. Crossmatch-compatible platelets improve corrected count increments in patients who are refractory to randomly selected platelets. Transfusion 1997;37:624-30.
58. O'Connell B, Lee EJ, Schiffer CA. The value of 10-minute post-transfusion platelet counts. Transfusion 1988;28:66-7.
59. Novotny VM. Prevention and management of platelet transfusion refractoriness. Vox Sang 1999;76:1-13.
60. Brand A. Alloimmune platelet refractoriness: incidence declines, unsolved problems persist. Transfusion 2001;41:724-6.
61. van Marwijk Kooy M, van Prooijen HC, Moes M, Bosma-Stants I, Akkerman JW. Use of leukocyte-depleted platelet concentrates for the prevention of refractoriness and primary HLA alloimmunization: a prospective, randomized trial. Blood 1991;77:201-5.
62. Williamson LM, Wimperis JZ, Williamson P et al. Bedside filtration of blood products in the prevention of HLA alloimmunization - a prospective randomized study. Alloimmunisation Study Group. Blood 1994;83:3028-35.
63. Sintnicolaas K, van Marwijk Kooij M, van Prooijen HC et al. Leukocyte depletion of random single-donor platelet transfusions does not prevent secondary human leukocyte antigen-alloimmunization and refractoriness: a randomized prospective study. Blood 1995;85:824-8.
64. Novotny VM, van Doorn R, Witvliet MD, Claas FH, Brand A. Occurrence of allogeneic HLA and non-HLA antibodies after transfusion of prestorage filtered platelets and red blood cells: a prospective study. Blood 1995;85:1736-41.
65. Kurz M, Greinix H, Hocker P et al. Specificities of anti-platelet antibodies in multitransfused patients with haemato-oncological disorders. Br J Haematol 1996;95:564-9.
66. Schnaidt M, Northoff H, Wernet D. Frequency and specificity of platelet-specific alloantibodies in HLA-immunized haematologic-oncologic patients. Transfus Med 1996;6:111-4.
67. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. The Trial to Reduce Alloimmunization to Platelets Study Group. N Engl J Med 1997;337:1861-9.